Topo IIα (C-15): sc-5346



The Boures to Overtion

BACKGROUND

DNA topoisomerase I and II (Topo I and Topo II) are nuclear enzymes that regulate the topological structure of DNA in eukaryotic cells by transiently breaking and rejoining DNA strands. Eukaryotic topoisomerases are capable of relaxing both positive and negative supercoils, whereas prokaryotic topoisomerases relax only negative supercoils. DNA topoisomerases play a role in DNA replication, recombination, and transcription and have been identified as targets of numerous anticancer drugs. Topo I, a ubiquitously expressed, soluble enzyme, acts by introducing a transient break in one strand of DNA, while Topo II acts by making a transient double-strand break. Topo II is encoded by two different genes to generate two distinct isoforms that are designated Topo II α and Topo II β . Topo II β and Topo II α , are largely homologous at their N-terminal three quarters, however, the C-terminal segments are considerably divergent, suggesting that these regions may mediate different cellular functions and account for the observed differential tissue expression patterns of the two isoforms.

CHROMOSOMAL LOCATION

Genetic locus: TOP2A (human) mapping to 17q21.2; Top2a (mouse) mapping to 11 D.

SOURCE

Topo $II\alpha$ (C-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of Topo $II\alpha$ of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-5346 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

Topo $II\alpha$ (C-15) is recommended for detection of Topo $II\alpha$ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000). Topo $II\alpha$ (C-15) is also recommended for detection of Topo $II\alpha$ in additional species, including equine, canine and porcine.

Suitable for use as control antibody for Topo II α siRNA (h): sc-36695, Topo II α siRNA (m): sc-36696, Topo II α shRNA Plasmid (h): sc-36695-SH, Topo II α shRNA Plasmid (m): sc-36696-SH, Topo II α shRNA (h) Lentiviral Particles: sc-36695-V and Topo II α shRNA (m) Lentiviral Particles: sc-36696-V.

Molecular Weight of Topo IIα: 170 kDa.

Positive Controls: HeLa nuclear extract: sc-2120, K-562 nuclear extract: sc-2130 or Jurkat nuclear extract: sc-2132.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



Topo II α (C-15): sc-5346. Western blot analysis of Topo II α expression in HeLa (**A**), K-562 (**B**) and Jurkat (**C**) nuclear extracts.

SELECT PRODUCT CITATIONS

- 1. Plo, I., et al. 2002. Overexpression of the atypical protein kinase C ζ reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells. J. Biol. Chem. 277: 31407-31415.
- Yoshida, Y., et al. 2003. p53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res. 63: 3729-3734.
- 3. Torigoe, T., et al. 2005. DNA topoisomerase II poison TAS-103 transactivates GC-box-dependent transcription via acetylation of Sp1. J. Biol. Chem. 280: 1179-1185.
- Igarashi, T., et al. 2007. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26: 4749-4760.
- Martins, R.P., et al. 2007. Decondensing the protamine domain for transcription. Proc. Natl. Acad. Sci. USA 104: 8340-8345.
- Sun, F., et al. 2007. Nuclear reprogramming: the zygotic transcription program is established through an "erase-and-rebuild" strategy. Cell Res. 17: 117-134.
- 7. Zheng, J., et al. 2008. Erasure of the paternal transcription program during spermiogenesis: the first step in the reprogramming of sperm chromatin for zygotic development. Dev. Dyn. 237: 1463-1476.
- 8. Thakurela, S., et al. 2013. Gene regulation and priming by topoisomerase $II\alpha$ in embryonic stem cells. Nat. Commun. 4: 2478.
- 9. Fan, A.X., et al. 2014. Genomic and proteomic analysis of transcription factor TFII-I reveals insight into the response to cellular stress. Nucleic Acids Res. 42: 7625-7641.



Try **Topo II** α (**G-6**): **sc-166934** or **Topo II** α (**A-8**): **sc-165986**, our highly recommended monoclonal alternatives to Topo II α (C-15).